Healthcare Industry News:  Siemens Healthcare 

Devices Oncology

 News Release - June 17, 2010

BSD Medical Reports Hyperthermia Use with Particle Therapy Highlighted at German Society of Radiation Oncology Meeting

SALT LAKE CITY--(HSMN NewsFeed)--BSD Medical Corporation (NASDAQ:BSDM ) today announced that hyperthermia in conjunction with particle therapy was highlighted at the annual meeting of the German Society of Radiation Oncology (DEGRO), which was recently held in Magdeburg, Germany. A total of 2,500 scientists and radiation oncologists attended the meeting.

Hyperthermia in combination with particle therapy (hadron therapy) was highlighted in a symposium titled “Hadrontherapy and Hyperthermia,” which was chaired by Jürgen Debus MD PhD, chairman of Radiation Oncology at the University Medical School of Heidelberg and CEO of HIT Heidelberg Ionbeam Therapycenter, and Eugen Hug MD, Director of the Proton Therapy Center of Paul Scherrer Institute at Villigen, Aargau, Switzerland.

Dr. Debus stated that UMS Heidelberg plans to conduct research on the use of hyperthermia and particle therapy, using both protons and heavy ions, at its state-of-the-art HIT Heidelberg Ionbeam Therapycenter, thus taking advantage of the strong rationale for combining hyperthermia with particle therapy. UMS Heidelberg has operated the HIT Heidelberg Ionbeam Therapycenter, which was contracted from Siemens Healthcare, since 2009. Particle therapy is an innovative form of radiation treatment that can deliver a higher targeted dose of radiation to the tumor while preserving surrounding tissue.

Stefan Bodis MD, chairman of radiation oncology at Kantonsspital Aarau, Switzerland, presented the clinical treatment projects for the newly installed BSD-2000 3D Hyperthermia System at their institution. Dr. Bodis reported that they are using hyperthermia in combination with particle therapy using protons for the treatment of deep seated tumors, including soft tissue sarcomas and pancreas cancer, in cooperation with the Proton Therapy Center of the PSI Paul Scherrer Institute.

Oliver Ott MD, University Medical School of Erlangen, Germany, presented an invited lecture highlighting the clinical results of hyperthermia in combination with radiation for the treatment of chest wall recurrence, bladder, and cervical cancer. Dr. Ott stated that hyperthermia and radiation therapy are routinely used to treat these patients. The Department of Radiation Oncology of UMS Erlangen operates a clinical hyperthermia unit that includes three dedicated hyperthermia treatment systems: the BSD-500 Hyperthermia System, the BSD-2000 3D Hyperthermia System, and the BSD-2000-3D MR Hyperthermia System. The striking advantages of image guided hyperthermia therapy were highlighted in the presentation.


The German Society of Radiation Oncology (DEGRO – Deutsche Gesellschaft für Radio-Onkologie) is the largest radiation oncology organization in Germany and has more than 2,500 members. The world’s longest running scientific journal in radiation oncology, “Strahlentherapie und Onkologie,” is the official publication of DEGRO.

About BSD Medical Corporation –

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the US. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Source: BSD Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.